Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma
Pilar Martinez‐Barranco, María García-Roa, Roberto Trelles‐Martínez, Karmele Arribalzaga, María Velasco, Carlos Guijarro, Javier Marcos, Carolina Campelo, Juan Manuel Acedo, Lucı́a Villalón, Pilar Ricard, María José García-Bueno, Elia Pérez‐Fernández, Gil Rodríguez‐Caravaca, Francisco‐Javier Peñalver
Abstract
INTRODUCTION: There is no consensus on the management of the coronavirus disease (COVID-19) in patients with secondary immunosuppression due to either an underlying hematological disease or to the effects of immunochemotherapy (ICT). Some of them may present persistent infection with multiple relapses of COVID-19, requiring several admissions. This study evaluated the clinical characteristics and outcomes after treatment of 5 patients with follicular lymphoma (FL), previously treated with ICT, who developed several episodes of COVID-19. METHODS: We analyzed the clinical evolution and response to treatment with antiviral agent, steroids, and convalescent plasma in 5 patients with FL and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) persistent infection. Reverse transcriptase polymerase chain reaction tests and peripheral blood immunophenotype were performed for all patients. RESULTS: All patients required hospitalization due to pneumonia with severity criteria and were re-admitted after a median of 22 days (13-42) from the previous discharge. They all showed B-cell depletion by immunophenotyping, and no traces of immunoglobulin antibodies against SARS-CoV-2 were detected in any of the cases. The survival rate was 80%. CONCLUSION: The combination therapy evidenced clinical benefits, demonstrating its capacity to control infection in immunosuppressed FL patients treated with ICT.